Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis

Language
en
Document Type
Article
Issue Date
2013-12-04
Issue Year
2012
Authors
Penner, Iris-Katharina
Stemper, Brigitte
Calabrese, Pasquale
Freedman, Mark S.
Polman, Chris H.
Edan, Gilles
Hartung, Hans-Peter
Miller, David H.
Montalbán, Xavier
Barkhof, Frederik
Editor
Abstract

Background: Cognitive dysfunction occurs at the earliest stages of multiple sclerosis (MS), including the stage of clinically isolated syndrome (CIS).

Methods: We evaluated the impact of interferon beta-1b (IFNβ-1b) 250 µg on cognitive performance during the CIS stage in the BENEFITstudy. Cognition was assessed by Paced Auditory Serial Addition Test-3” (PASAT-3”) scores.

Results: Improvement in PASAT-3” score from baseline to year two was greater for IFNβ-1b treatment than placebo in patients not reaching clinically definite MS (CDMS) by year two. The treatment effect was maintained at year five and was statistically significant.

Conclusions: To conclude, early IFNβ-1b treatment had a sustained positive effect on PASAT-3” score over the 5-year BENEFIT study.

Journal Title
Multiple Sclerosis Journal
Volume
18
Issue
10
Citation

Multiple Sclerosis Journal 18.10 (2012): S. 1466-1471. 03.12.2013 http://msj.sagepub.com/content/18/10/1466.abstract

Zugehörige ORCIDs